These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 16161005)

  • 1. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
    Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3.
    Lin J; Tang H; Jin X; Jia G; Hsieh JT
    Oncogene; 2002 May; 21(19):3082-8. PubMed ID: 12082540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
    Skomedal H; Kristensen GB; Lie AK; Holm R
    Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
    Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
    Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
    Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
    Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 overexpression in recurrent endometrial carcinoma.
    Pijnenborg JM; van de Broek L; Dam de Veen GC; Roemen GM; de Haan J; van Engeland M; Voncken JW; Groothuis PG
    Gynecol Oncol; 2006 Feb; 100(2):397-404. PubMed ID: 16271749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.
    Guillot C; Falette N; Paperin MP; Courtois S; Gentil-Perret A; Treilleux I; Ozturk M; Puisieux A
    Oncogene; 1997 Jan; 14(1):45-52. PubMed ID: 9010231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
    Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
    Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases.
    Leventaki V; Rodic V; Tripp SR; Bayerl MG; Perkins SL; Barnette P; Schiffman JD; Miles RR
    Br J Haematol; 2012 Sep; 158(6):763-71. PubMed ID: 22845047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
    Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
    Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
    Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
    Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
    Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.